Chemaphor in U.S. spotlight

4/20/2012 4:09:49 PM | Interview with Bob Weir

1848 Reads

“Prospects are good for companies aiming to develop products for animals because people are willing to spend more money to ensure that their pets are healthy.”

Stockhouse talks to Bob Weir, President and Chief Executive Officer of eResearch Corp. in Toronto.

Focus: Providing equity research on small cap biotech and mining companies

Can you give me your perspective on what is happening in the market right now?

“Like junior mining companies, small cap biotech firms need to continually come back to the market to raise funds for research and development. Prospects are good for companies aiming to develop products for animal care because people are willing to spend more money to ensure that their pets are healthy.”

What is your take on Ottawa company Chemaphor Inc.?

“We think that this company has incredible potential.’’ On April 19, Chemaphor (TSX: V.CFR, Stock Forum) announced that it has received its first order for Oximunol Chewables for the veterinary market in the U.S. Oximunol chewables contain the active ingredient OxC-beta, which works with a dog’s immune system to optimize the animal’s overall health and wellbeing. “Chemaphor has some sales in Canada. But this first U.S. order for Oximunol will attract a lot of attention in the U.S.”

Trading at 8 cents this week, Chemaphor has a market cap of $6.7 million, based on 83.8 million shares outstanding. The 52-week range is 15 cents and 4 cents.

Are there any other companies that you are watching in this space?

Bioniche Life Sciences Inc. (TSX: T. BNC, Stock Forum) is a Belleville, Ont.-based pharmaceutical company and developer of products for animal and human health. “The company has developed an anti-cancer bladder product that is expected to be on the market by 2015.” Trading at 54 cents this week, Bioniche has a market cap of $55.7 million, based on 103.2 million shares outstanding. The 52-week range is $1.26 and 47 cents.

ABOUT THE AUTHOR

Interview with Bob Weir

add to favorites

Stockhouse Conflict and Disclosure Policy:

Stockhouse publishing Ltd., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.

Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.

Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.

Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.

Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.